Medtronic (MDT) announced primary endpoint results from the SPYRAL AFFIRM post-approval study of the Symplicity Spyral renal denervation system
ORIGINAL · NewsquawkMedtronic (MDT) announced primary endpoint results from the SPYRAL AFFIRM post-approval study of the Symplicity Spyral renal denervation systemRead originalHide original
The study showed statistically significant and clinically meaningful blood pressure reductions at six months, including office, home, and 24-hour ambulatory blood pressure, with no increase in antihypertensive medications. Six-month results in the US primary endpoint cohort were compared with a prespecified performance goal.
Medtronic announced SPYRAL AFFIRM primary endpoint results, but the supplied record contains no details of the findings or study.
News detail
The study showed statistically significant and clinically meaningful blood pressure reductions at six months, including office, home, and 24-hour ambulatory blood pressure, with no increase in antihypertensive medications. Six-month results in the US primary endpoint cohort were compared with a prespecified performance goal.
Related stocks
1 stocks
What do investors think?
StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.